



Where others stop, we start and add value

Reinventing Existing Medicines

VFB Soirées – Company Update
13 October 2026

Nice to meet you!



Forward-Looking Statements



This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, "presentation" means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person's organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company

Tonight: Three Key Questions



1

What makes Hyloris different?

A smarter approach to develop better medicines

2

Where will our growth come from?

Our products, priorities and future opportunities


3

How do we turn progress into shareholder value?

Growing revenues, disciplined investment and future milestones



Pharma needs faster & more affordable innovation



Reinvent existing & Invent new medicines



Improve DOSAGE FORM and/or change
ROUTE of administration of existing
medicines

Target to be **MORE EFFECTIVE – MORE
PREDICTABLE – MORE CONVENIENT**



Repurpose existing medicine for a
NEW therapeutic INDICATION (use)

**NEW PRODUCT – NEW FIELD
NEW MARKET**



New Chemical Entity
using own pathway
based on applicable law

REFORMULATING + REPURPOSING

Maximise use (non) clinical data of
approved drug product

Our Value Proposition: Driving faster innovation

Reducing Time-to-Market, Cost & Clinical Burden



Traditional model for NCE's & Biologics

average

15
years

Hyloris - model

up to

7
years



Approved molecules



Reduction time (pre)clinical development




Needs of Stakeholders taken into account



Leverage public data by adding Innovative use

FDA's 505(b)(2) pathway (or equivalent) as the engine



*Not adjusted for inflation / exchange rate differences.



Asset-light: Hyloris develops, partners commercialise

Hyloris innovates & develops

Focused team in Liège: 54 people, 13 nationalities

Formulation, clinical, regulatory & IP



Partners manufacture & commercialise

AFT, Orion, Avenacy, Rosemont,...

Manufacturing, market access and sales reach



Hyloris generates revenue

Upfronts, milestones, royalties & profit share

No own factory or global sales force

Ad hoc supply chain, API supply, self-commercialization remains an option depending context

A broad, high – value development portfolio driving sustainable growth

30+
products

25+
value-added

Commercial Partnerships (Products Launched)

4

Maxigesic IV	(value added / non-opioid analgesic)
Sotalol IV	(value added / cardiovascular)
Podofilox Gel	(high barrier generic / infectious diseases)
Tranexamic Acid IV RTU	(high barrier generic/ bleeding)

In Development

26+

Pending filings for approval

2

Atomoxetine oral liquid solution
Valacyclovir powder for suspension
Dofetilide IV (for submission)

From pipeline to commercial progress



MARKETED PRODUCTS Growing our revenue base

- Four products commercialised
- First royalties and profit share from **Tranexamic Acid IV RTU**
- **Podofilox Gel** back on the market in Q2

NEW PARTNERSHIPS Extending our reach

- **Orion**: Pantoprazole IV RTU in Europe
- Maxigesic IV: expansion **AFT** agreements for China and Japan
- Tranexamic Acid IV RTU: **Avenacy** – US & Switzerland
- Partners bring local market access

FOCUSED INVESTMENT Choosing our priorities

- Advance programmes with the strongest potential
- Three programmes discontinued
- Allocate spending based on evidence

From Pipeline to Commercialisation





Broad, innovative cardiovascular portfolio

Product	Route/Form	Indication	Formulation	Clinical Development	Regulatory Filing and approval	Target Market
			UP TO 7 YEARS			
● Sotalol IV	IV	Atrial Fibrillation	Partnered in the U.S. with AltaThera			U.S.
● Aspirin IV	IV	Acute Coronary Syndrome				WW
★ ● Milrinone ER	Oral solid	Late-stage HF with LVAD				WW
★ ● Dofetilide IV	IV	Atrial Fibrillation				U.S.
● HY-074	IV	Acute Coronary Syndrome				WW
● Metolazone IV	IV	Congestive Heart Failure				WW

ER: Extended-Release

HF: Heart Failure

LVAD: battery-operated, mechanical surgically implanted pump, which helps the left ventricle of the heart pump blood

● Reformulating

● Repurposing

○ NCE/NBE (ARBM-101)

★ Stars

■ Optimal commercialization strategy currently under evaluation

■ Commercialised with partner

■ Intended to be commercialised with partners



Other value-added portfolio

		Product	Route/Form	Indication	Formulation	Clinical Development	Regulatory Filing and approval	Target Market
					UP TO 7 YEARS			
●		Maxigesic® IV	IV	Post-operative pain	Co-development with AFT Pharmaceuticals			WW
●		Podofilox Gel	Topical	Ext. genital/perianal warts	Partnered in the U.S. with Padagis			U.S.
●		Xtraza	Oral Mouth Rinse	Specific dental indication				EU+selected
★	●	Alenura™	Instillation	IC / Painful Bladder Syndrome				WW
	●	Miconazole DB	Topical	rVVC/BV**				WW
	●	PTX-252	IV	AML				WW
★	○	Atomoxetine	Oral Liquid	ADHD				WW
	●	Valacyclovir	Oral Liquid	Viral infection				WW*
	●	HY-083 (TRPV1-ag.)	Nasal spray	Idiopathic Rhinitis				WW
★	●	Phosphate	Oral Liquid	Hypo Phosphatemia				WW
	●	HY-089	Local-acting dose	Burning Mouth Syndrome		Co-development with AFT Pharmaceuticals		WW
★	●	HY-094	Injection	Iron Deficiency Anemia		Co-development with AFT Pharmaceuticals		WW
★	○							

Other than Podofilox Gel, our high barrier generic products, TXA RTU and Fusidic Acid Cream have not been included in the above overview.

ADHD: attention deficit hyperactivity disorder; Miconazole-DB: miconazole-domiphen bromide; rVVC: recurring vulvovaginal candidiasis; BV: Bacterial vaginosis

AML: Acute Myeloid Leukemia; SCLC: Small cell Lung Cancer, Pleocid Agent (or PTX-252)

* U.S., major European markets, Canada, Mexico, Australia, China, South Korea and the GCC countries

** BV under investigation



Other value-added portfolio, cont'd

Product		Route/Form	Indication	Formulation	Clinical Development	Regulatory Filing and approval	Target Market
				UP TO 7 YEARS			
★ ●	HY-095 (PPI) LAI	Injection	Equine Gastric Ulcer Syndrome				WW
★ ●	Pantoprazole RTU	Injection	GERD and EE				WW
●	Ondansetron ER	Tablet	Nausea/vomiting				WW ex. U.S. MX and CA
○	Suramin IV	Injection	Human African Trypanosomiasis**				WW
●	HY-098	Topical	Rare, inherited skin disorder				WW
○	Methanobactin (ARBM-101)	Injection	Wilson's disease				Europe and Turkey

* Worldwide, except U.S., Canada, and Mexico

** A Phase 2 trial has been done for an additional indication, autism spectrum disorder (ASD)



What sets us apart:

Product Selection – ROI – Risk Profile

- CMO search – efficiency
- Cost development
- Worldwide partner/distribution network
- Creative thinking
- Leading reference
- Entrepreneurship
- Broad variety of products



Center of Excellence for R&D and Regulatory

- Impressive KOL network Worldwide
- Strategic Insights to indentify unmet medical needs
- Patient-centric approach
- Targeted Investigator Initiated Trials (IIT)
- Well-positioned Proof of Concept
- Early-stage & ongoing discussions with Health Authorities
- Successful regulatory submission strategies
- Strong IP creation & protection

Our Product Portfolio (as publicly announced)

3 Strategic Focus Groups for Growth



MAVERICKS

A high-potential product backed with clinical evidence and significant commercial potential:
medium risk – high spent – high success – high value

5



CORE DRIVERS

A catalyst product building a strong recurring revenue base at near term:
low risk – low spent – high success – medium value

15



PROMISING SEEDS

An early-stage product pending clinical validation:
high risk – medium spent – low success - moonshot potential

6

Our Product Portfolio

3 Strategic Focus Groups for Growth

Product Fiches shared separately on website



MAVERICKS

HY-094 (Iron Deficiency Anemia) ★
Milrinone ER ★
Miconazole DB
Suramin IV
Alenura™ ★

Reformulating
Repurposing
NCE



CORE DRIVERS

Maxigesic® IV
Sotalol IV
Podofilox Gel (Generic)
TXA Oromucosal Solution(XTRAZA™)(EU)
Metolazone IV
Valacyclovir Oral Suspension
Atomoxetine Oral Liquid
Ondansetron ER
Dofetilide IV ★
Phosphate Oral Liquid
Pantoprazole IV RTU ★
HY-074 (ACS)
Aspirin IV
Tranexamic Acid RTU (Generic)
Fusidic Acid (Generic)



PROMISING SEEDS

HY-083 (Idiopathic Rhinitis) ★
HY-095 (Equine Gastric Ulcers) ★
HY-098 (skin disorder) ★
HY-089 (BMS) ★
HY-086 (PTX-252) (AML) ★
HY-106 Methanobactin (Wilson's) ★

What moves next in each group



MAVERICKS

The biggest value step

- HY-094 (IV iron): Phase 3 IND cleared
- Milrinone ER: orphan drug designation, Phase 1
- Alenura™: Phase 2 111 trial fully recruited

CORE DRIVERS

Recurring revenue engine

- 4 products commercialized
- Atomoxetine oral liquid: NDA filed by Rosemont
- Dofetilide IV & Aspirin IV: submissions planned
- Pantoprazole IV RTU: Orion deal for Europe

SEEDS but also DISCIPLINE

Choosing is also stopping

- Stopped: XTRAZA® U.S. Phase 3, HY-075, HY-091
- Promising Seeds: limited budget until proven
- U.S. cardiovascular portfolio: best route to market, incl. partnerships

HY-094 Ferric for injection

Indication: Iron Deficiency Anemia (IDA)

- Innovative NCE injectable iron therapy designed to overcome limitations of current treatments for better convenience and tolerability
- Targeting global intravenous iron drug market forecasted to more than USD 7.41 billion by 2033¹
- Co-development deal with AFT Pharmaceuticals in March 2025
- Data shows potential reduction in dosing needs, fewer side effects, and lower toxicity vs. standard care
- 146-patient trial demonstrated fewer complications (2.7% vs. 29.7%) and no hypophosphatemia risk
- IND filing with FDA underway; ~1,000-patient global Phase III trial starting soon
- Hyloris' estimated development costs below EUR 7 million

25% of the global population are anemic²

Corresponding to ~ 1.9 billion people



66% of the anemic burden due to IDA²

Corresponding to ~ 1.3 billion people

Market for intravenous iron drugs³

USD 3.2 bn in 2023 growing to >USD 7.4bn in 2033.

Global Intravenous Iron Drugs Market Size 2023 to 2034 (USD Billion)



1) <https://www.biospace.com/intravenous-iron-drugs-market-size-to-worth-around-us-7-41-billion-by-2033>

2) In 2021: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10465717/>

3) <https://www.precedenceresearch.com/intravenous-iron-drugs-market>



Indication: Interstitial Cystitis/Bladder Pain Syndrome


- Defect in inner lining of the bladder = chronic, recurring discomfort & pain
- Alenura 15mL prefilled syringe with a dual mode of action:
 - Alkalinised lidocaine: penetrates bladder wall and provides **immediate pain relief**
 - Heparin: augments bladder mucous, anti-inflammatory and anti-bacterial properties = **prolonged pain relief**
 - **Unique combination**
- 4-arm (controlled double-blind multi-center) clinical trial in the U.S. ongoing, FPFV in June 2023

✓ Targeting first treatment for acute pain flares


Patients/year (U.S.)	>6 million
Instillation procedures (U.S.)	3 million

Proven pain reduction in 2 controlled Ph2 trials

% Change in pain over time



% Change in pain over time



HY-083



Indication: **Idiopathic Rhinitis** - chronic rhinitis without a known cause

- Symptoms: Runny nose, stuffy nose, sneezing fits without a medical diagnosis (allergies, infection, inflammation, ...)
 - Impacting quality of life daily (sleep patterns, drowsiness, irritability, poor concentration)
 - Molecule with known mechanism of action: blocks TRPV1 receptor in the nose
 - Both rapid and sustainable relief
 - Discovery of TRPV1-receptors was awarded the 2021 Nobel Prize

✓ Targeting the first reliable treatment

Market size	7% of population
Absolute numbers	~ 19 million patients in the US ~ 25,8 million patients in Europe
Seeks specialist treatment	13% of the above, following ~8 years of trial and error




**No systemic exposure
detected in Phase 1 trial**



The turning point is visible in the numbers

H1 2026 vs H1 2025, € million



+56%

Revenue, driven by upfront and regulatory milestones. H1 2026 saw first royalties on 4th commercialized product Tranexamic Acid IV RTU

-47%

lowest Hy net loss since IPO (2020)

+47%

Operating income, driven by upfront and regulatory milestones. H1 2026 saw first royalties on 4th commercialized product Tranexamic Acid IV RTU



A solid financial basis

Funding

Intent additional funding
confirmed by Comfort
Letter CEO

€8.7M

cash at 30 June 2026

€0*

financial debt

cash runway into

Q4 2027

Financial flexibility

Extra room to execute while licensing deals bring in
upfront payments

Costs under control: R&D –16% in H1 2026

Multiple ways to improve cash runway (ability to delay or
defer some activities and/or access to financial support)

Stronger governance

Compliance embedded



Three ways for further growth business potential

Different revenue opportunities — not dependent on a single product

1

Grow existing products

Maxigesic IV · Sotalol IV · Tranexamic Acid RTU

More sales → potential growth in recurring royalties

2

Launch more products

Atomoxetine oral liquid · Valacyclovir suspension · Aspirin IV

Approvals and launches → potential new royalties


3

Sign new partnerships

Pantoprazole IV RTU (partnered) · Feramyl & Alenura (in development)

New agreements → upfronts, milestones and future royalties

The Hyloris Share 2026



Total number of outstanding voting rights (denominator)	28,000,374
Total number of securities carrying voting rights not yet used	705,480
Share capital (excluding share premium)	€140,001



For founders: Based on transparency notifications and latest denominator; based on online FSMA notifications managers' transactions – For other named shareholders: Based on the number of shares held as declared in the most recent transparency declaration and the total number of outstanding voting rights (March 26, 2026).

Key takeaways



We make existing medicines better – and turn our pipeline into growing recurring revenue.

Proven model

Faster, cheaper, lower risk: ≤ 7 years and $\sim\text{€}7\text{M}$ or less per product, with partners

Sharper strategy

Core Drivers for revenue, Mavericks for value, discipline in what we stop

Execution

+56% revenue, lowest H1 loss since IPO, $\text{€}6\text{M}$ additional funding secured

Where others stop, we start and add value.



Value Starts Here

Hyloris Pharmaceuticals SA - 2026



HQ: Boulevard Patience Et Beaujonc N°3/1
4000 Liège, Belgium



+32(0)4 346 02 07



contact@hyloris.com
investorrelations@hyloris.com